(616 Kb) May 2026

: For those who stopped the medication, the median time until they did so was only 7 months .

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). (616 KB)

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics : For those who stopped the medication, the

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months. The goal was to see if the high

The search for a "616 KB" article points directly to a significant medical study titled

The study highlighted a few differences between "real-world" patients and those in trials:

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort